<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04545502</url>
  </required_header>
  <id_info>
    <org_study_id>PANTHER-001</org_study_id>
    <nct_id>NCT04545502</nct_id>
  </id_info>
  <brief_title>A Prospective and Retrospective, Multi-Centre, Post-Market, Non-Interventional Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches</brief_title>
  <acronym>PANTHER</acronym>
  <official_title>A Prospective and Retrospective, Multi-Centre, Post-Market, Non-Interventional Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascutek Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascutek Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to collect safety and performance data on all commercially&#xD;
      available Terumo Aortic knitted and woven grafts, and cardiovascular patches in standard&#xD;
      clinical practice.&#xD;
&#xD;
      Data will be collected both retrospectively and prospectively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2021</start_date>
  <completion_date type="Anticipated">January 2033</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Operative Death</measure>
    <time_frame>1 Year</time_frame>
    <description>30 Day or In-Hospital Mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft Leakage</measure>
    <time_frame>1 Year</time_frame>
    <description>Device Failure: The presence of leakage or excessive bleeding through graft/patch</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Endpoints</measure>
    <time_frame>1 Year</time_frame>
    <description>Device failures, requirement for reintervention or device related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Endpoints</measure>
    <time_frame>1 Year</time_frame>
    <description>Rifampicin or heparin soaking, procedure related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoints</measure>
    <time_frame>1 Year</time_frame>
    <description>Occurrence of the following: Mortality, Ischemia, Occlusion, Thrombosis, Haemmorrhage, Rupture, Pseudoaneurysm, Stroke</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Aneurysm</condition>
  <condition>Dissection</condition>
  <condition>Aortic Root Aneurysm</condition>
  <condition>Aortic Root Dissection</condition>
  <condition>Carotid Artery Injuries</condition>
  <condition>Aortic Arch</condition>
  <condition>Bypass Extremity Graft</condition>
  <condition>Occlusive Vascular Disease</condition>
  <condition>Aortic Diseases</condition>
  <arm_group>
    <arm_group_label>Gelsoft Plus - Straights and Bifurcated</arm_group_label>
    <description>Patients with aneurysmal or occlusive disease, including those with connective tissue disorders who have received/will receive a Gelsoft Plus Straight or Bifurcate, implanted in the abdomen or peripheral arteries in the last 5 years and from study launch onwards.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gelsoft Plus - Extra-Anatomical</arm_group_label>
    <description>Any patients who have received/will receive a Gelsoft Plus Extra-Anatomical supported or unsupported graft, implanted for: axillary-femoral bypass, femoral-femoral bypass or femoral-popliteal bypass in the last 5 years and from study launch onwards.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiovascular Patches - Gelseal, Gelsoft, Thin Wall</arm_group_label>
    <description>Patients who have been implanted with/require a cardiovascular patch for: thoracic vessel repair with a Gelseal Cardiovascular Patch; abdominal or peripheral vessel repair with a Gelsoft Cardiovascular Patch; or carotid endarterectomy with a Thin Wall Carotid Patch in the last 5 years and from study launch onwards.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gelweave - Abdominal, Thoracic, Thoracoabdominal</arm_group_label>
    <description>Patients who, due to either aneurysmal or occlusive disease, have had/require vascular repair of one of the following, implanted in the last 5 years and from study launch onwards:&#xD;
Abdominal aorta, arteries arising from the abdominal aorta or peripheral arteries including femoral, iliac and popliteal arteries.&#xD;
Thoracic aorta or arteries arising from the thoracic aorta.&#xD;
Abdominal and thoracic aorta requiring a thoracoabdominal repair</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gelweave - Valsalva</arm_group_label>
    <description>Patients who have had/require aortic root repair using valve sparing or valve replacing procedures, with or without replacement of the aortic arch, implanted in the last 5 years and from study launch onwards.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gelsoft Plus Vascular Graft</intervention_name>
    <description>Gelatin coated, knitted vascular prosthesis implanted to act as a conduit for channeling blood during repair of damaged or diseased vessels.</description>
    <arm_group_label>Gelsoft Plus - Straights and Bifurcated</arm_group_label>
    <other_name>Gelsoft Plus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vascular Bypass Graft</intervention_name>
    <description>Gelatin coated, knitted vascular prosthesis implanted to act as an extra-anatomical bypass for channeling blood during repair of damaged or diseased vessels.</description>
    <arm_group_label>Gelsoft Plus - Extra-Anatomical</arm_group_label>
    <other_name>Gelsoft Plus Extra Anatomical</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiovascular Patch</intervention_name>
    <description>Cardiovascular knitted polyester patches are frequently used to treat the carotid or femoral arteries to prevent stroke and repair damage to vessels.</description>
    <arm_group_label>Cardiovascular Patches - Gelseal, Gelsoft, Thin Wall</arm_group_label>
    <other_name>Gelseal Patch</other_name>
    <other_name>Gelsoft Patch</other_name>
    <other_name>Thinwall Patch</other_name>
    <other_name>Cardiovascular Fabrics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gelweave Vascular Graft</intervention_name>
    <description>The Gelweave woven polyester vascular graft allows replacement of large sections of arteries and, following anastomosis to the native blood vessel, provides a stable conduit for blood flow.</description>
    <arm_group_label>Gelweave - Abdominal, Thoracic, Thoracoabdominal</arm_group_label>
    <other_name>Gelweave</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gelweave Valsalva Vascular Graft</intervention_name>
    <description>This woven polyester graft is designed to match the aortic root anatomy and is implanted to repair or replace a portion of the aorta in case of an aneurysm, dissection or coarctation at the level of the thoracic aorta.</description>
    <arm_group_label>Gelweave - Valsalva</arm_group_label>
    <other_name>Gelweave Valsalva</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who require treatment, or have already received treatment within the last 5 years,&#xD;
        with the following commercially available Terumo Aortic knitted and woven grafts and&#xD;
        cardiovascular patches:&#xD;
&#xD;
          -  Gelsoft Plus - Straights and Bifurcated&#xD;
&#xD;
          -  Gelsoft Plus - Extra-Anatomical&#xD;
&#xD;
          -  Cardiovascular Patches - Gelseal, Gelsoft and Thin Wall&#xD;
&#xD;
          -  Gelweave - Abdominal, Thoracic and Thoracoabdominal&#xD;
&#xD;
          -  Gelweave - Valsalva This is a non-interventional study and therefore only patients who&#xD;
             would normally receive treatment with a Terumo Aortic devices as part of standard&#xD;
             treatment at the participating institution can be enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must meet all of the following inclusion criteria in order to be eligible for&#xD;
             inclusion in the study:&#xD;
&#xD;
        All Patients:&#xD;
&#xD;
          -  Patient meets the minimum age as per local regulations at time of consent&#xD;
&#xD;
          -  Patient requires treatment with study device(s) according to the IFU(s)&#xD;
&#xD;
          -  Patient is willing and able to comply with all SOC procedures and study visits&#xD;
&#xD;
          -  Patient or their legally authorised representative (LAR) has given written informed&#xD;
             consent to participate in study, including consent to collect data retrospectively&#xD;
&#xD;
               -  For prospective emergency patients, retrospective consent is permissible&#xD;
&#xD;
               -  For retrospective patients who are deceased at time of enrollment, local EC&#xD;
                  regulations relating to consent process should be followed.&#xD;
&#xD;
        Retrospective Patients only:&#xD;
&#xD;
          -  Patient has a minimum of 1 year post-operative follow-up data available, or complete&#xD;
             data to death.&#xD;
&#xD;
          -  Patient implant date is no more than 5 years prior to study start date.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient who meets any of the following exclusion criteria will be excluded from&#xD;
             participation in the study:&#xD;
&#xD;
               -  Patient is unable or unwilling to comply with the SOC procedures or follow-up&#xD;
                  regime&#xD;
&#xD;
               -  Patient is contraindicated per the device IFU&#xD;
&#xD;
               -  Patient has any other medical, social or psychological problems that in the&#xD;
                  opinion of the investigator preclude them from receiving this treatment and the&#xD;
                  procedures and evaluations pre- and post-procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Study Manager</last_name>
    <phone>+44 141 812 5555</phone>
    <email>r.smith1@terumoaortic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>TA UK Clinical Research</last_name>
    <phone>+44 141 812 5555</phone>
    <email>clinicalresearchuk@terumoaortic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of South Florida - Tampa General</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thanh Tran</last_name>
      <email>tqtran@usf.edu</email>
    </contact>
    <investigator>
      <last_name>Murray Shames</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Corvera, MD</last_name>
      <email>jcorvera@iuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Joel Corvera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chad Hughes</last_name>
      <email>gchad.hughes@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Chad Hughes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean Yamaguchi</last_name>
      <email>YAMAGUCHID@ECU.EDU</email>
    </contact>
    <investigator>
      <last_name>Dean Yamaguchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terence Semenec</last_name>
      <email>terence.semenec@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Jae Cho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Wu</last_name>
      <email>James.Wu@lvhn.org</email>
    </contact>
    <investigator>
      <last_name>James Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Newton, MD</last_name>
      <email>daniel.newton@vcuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Newton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Moreels</last_name>
      <email>nathalie.moreels@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Nathalie Moreels</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge Kortrijk</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Lerut</last_name>
      <email>philip.lerut@azgroeninge.be</email>
    </contact>
    <investigator>
      <last_name>Philip Lerut</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Verbrugghe</last_name>
      <email>peter.verbrugghe@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Peter Verbrugghe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Labrousse</last_name>
      <email>louis.labrousse@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Louis Labrousse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg - Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick Georg</last_name>
    </contact>
    <investigator>
      <last_name>Yannick Georg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Chaufour</last_name>
    </contact>
    <investigator>
      <last_name>Xavier Chaufour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Hinterseher</last_name>
      <email>gefaesschirurgie@charite.de</email>
    </contact>
    <investigator>
      <last_name>Irene Hinterseher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinik Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Probst</last_name>
      <email>chris.probst@ukbonn.de</email>
    </contact>
    <investigator>
      <last_name>Chris Probst</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNIVERSITÄTSKLINIKUM FREIBURG/Bad Krozingen</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Lechner</last_name>
      <email>gabriele.lechner@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Martin Czerny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UKE Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Debus</last_name>
      <email>s.debus@uke.de</email>
    </contact>
    <investigator>
      <last_name>Sebastian Debus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Etz</last_name>
      <email>Christian.Etz@helios-gesundheit.de</email>
    </contact>
    <investigator>
      <last_name>Christian Etz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Heart and Vascular Center</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoltan Szeberin, MD</last_name>
      <email>szeberin.zoltan@med.semmelweis-univ.hu</email>
    </contact>
    <investigator>
      <last_name>Zoltan Szeberin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital (Ziekenhuis) Breda</name>
      <address>
        <city>Breda</city>
        <zip>4818</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L. van der Laan, Prof. Dr.</last_name>
      <email>lvanderlaan@amphia.nl</email>
    </contact>
    <investigator>
      <last_name>L. van der Laan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vascular Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Artery Injuries</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Aortic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

